<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Mirabegron" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Mirabegron</book-part-id>
      <title-group>
        <title>Mirabegron</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Minoxidil" document-type="chapter">Minoxidil</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Mirtazapine" document-type="chapter">Mirtazapine</related-object>
    </book-part-meta>
    <body>
      <sec id="Mirabegron.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Mirabegron.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Mirabegron is a beta-3 adrenergic agonist that is used for treatment of overactive bladder syndrome. Mirabegron has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.</p>
        </sec>
        <sec id="Mirabegron.Background">
          <title>Background</title>
          <p>Mirabegron (mir" a beg' ron) is a synthetic beta-3 adrenergic agonist which binds to receptors in the bladder that causes relaxation of the detrusor smooth muscle and results in an increase in the bladder capacity. Mirabegron has been evaluated as therapy of the overactive bladder syndrome, a condition marked by urgency, frequency, nocturia and incontinence that occurs most commonly in older women. Other therapies of overactive bladder include anticholinergics, but these are only partially effective and can have troublesome side effects, particularly in the elderly. In several short term clinical trials, mirabegron was found to increase voided volume and decrease episodes of incontinence and urinary frequency modestly. Mirabegron was approved for use in the United States in 2012 as treatment of overactive bladder with symptoms of urgency, incontinence, and frequency. In 2021, the indications were expanded to include treatment of children with neurogenic detrusor muscle instability using formulations of mirabegron granules. Mirabegron is available as 25 and 50 mg extended-release tablets under the brand name Myrbetriq. The typical dose in adults is 25 to 50 mg orally once daily. Mirabegron is also available as granules in solution of 8 mg/mL, and the typical dose in children is 48 or 80 mg daily. Side effects are not common, but can include nausea, diarrhea, constipation, dizziness, tachycardia, palpitations, hypertension, and headache. Rare, but potentially severe side effects include hypertension, urinary retention, and hypersensitivity reactions, angioedema, and rash.</p>
        </sec>
        <sec id="Mirabegron.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In preregistration clinical trials, serum aminotransferase elevations were uncommon and mild in patients treated with mirabegron and rates of serum enzyme elevations were similar to those with placebo treatment. Among several thousands of patients treated, there were no episodes of clinically apparent liver injury. Since its approval and more widescale use, there have not been any published reports of hepatotoxicity attributed to mirabegron. However, the product label for mirabegron mentions occasional elevations in ALT and AST associated with treatment as well as a case of Stevens Johnson syndrome with aminotransferase elevations. Thus, mirabegron may cause hepatic injury as a part of a generalized hypersensitivity reactions.</p>
          <p>Likelihood score: E* (unproven but suspected rare cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Mirabegron.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The possible cause of liver injury due to mirabegron is not known but might result from a generalized hypersensitivity reaction. Mirabegron is metabolized in part by CYP 2D6, but drug-drug interactions with agents that inhibit or induce this enzyme are uncommon.</p>
          <p>Drug Class: Urologic Agents, Overactive Bladder Syndrome Agents</p>
          <p>Other Drugs in the Subclass, Overactive Bladder Syndrome Agents: <related-object link-type="booklink" source-id="livertox" document-id="Darifenacin" document-type="chapter">Darifenacin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Fesoterodine" document-type="chapter">Fesoterodine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Flavoxate" document-type="chapter">Flavoxate</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Hyoscyamine" document-type="chapter">Hyoscyamine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Oxybutynin" document-type="chapter">Oxybutynin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Solifenacin" document-type="chapter">Solifenacin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Tolterodine" document-type="chapter">Tolterodine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Trospium" document-type="chapter">Trospium</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Vibegron" document-type="chapter">Vibegron</related-object></p>
        </sec>
      </sec>
      <sec id="Mirabegron.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Mirabegron &#x02013; Myrbetriq&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Urologic Agents</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Mirabegron">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Mirabegron.CHEMICAL_FORMULA_AND_STRUCTUR">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Mirabegron.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Mirabegron.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Mirabegron.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO.</th>
                <th id="hd_h_Mirabegron.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Mirabegron.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Mirabegron.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Mirabegron</td>
                <td headers="hd_h_Mirabegron.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135262850">223673-61-8</ext-link>
</td>
                <td headers="hd_h_Mirabegron.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C21-H24-N4-O2-S</td>
                <td headers="hd_h_Mirabegron.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135262850" document-id-type="sid" document-type="summary" object-id="135262850" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Mirabegron.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 14 July 2023</p>
        <ref-list id="Mirabegron.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Mirabegron.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999 before the availability of mirabegron).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.westfall.2018">
            <mixed-citation publication-type="book">Westfall TC, Macarthur H, Westfall DP. Adrenergic agonists and antagonists. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 191-223.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.herschorn.2013.313">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Herschorn</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barkin</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Castro-Diaz</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Frankel</surname>
<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Espuna-Pons</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gousse</surname>
<given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>St&#x000f6;lzel</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the &#x003b2;<sub>3</sub>adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.</article-title>
<source>Urology</source>
<year>2013</year>; <volume>82</volume>: <fpage>313</fpage>-<lpage>20</lpage>.<annotation><p><italic toggle="yes">(Among 1306 patients with overactive bladder syndrome treated with mirabegron [25 or 50 mg] or placebo daily for 12 weeks, episodes of incontinence and numbers of micturitions per day decreased with mirabegron, and side effects were mild and "the overall incidence of hepatic treatment emergent adverse events was similar across treatment groups; most were mild or moderate").</italic></p></annotation><pub-id pub-id-type="pmid">23769122</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.nitti.2013.619">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nitti</surname>
<given-names>VW</given-names></string-name>, <string-name name-style="western"><surname>Khullar</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>van Kerrebroeck</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Herschorn</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cambronero</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Angulo</surname>
<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Blauwet</surname>
<given-names>MB</given-names></string-name>, <etal>et al.</etal>
<article-title>Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.</article-title>
<source>Int J Clin Pract</source>
<year>2013</year>; <volume>67</volume>: <fpage>619</fpage>-<lpage>32</lpage>.<annotation><p><italic toggle="yes">(In a pooled analysis of 3 placebo controlled trials, 3542 patients with overactive bladder syndrome were treated with mirabegron [25, 50 or 100 mg] or placebo daily for 12 weeks; adverse event rates were no different with mirabegron than placebo; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">23692526</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.khullar.2013.283">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Khullar</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Amarenco</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Angulo</surname>
<given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Cambronero</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>H&#x000f8;ye</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Milsom</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Radziszewski</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Efficacy and tolerability of mirabegron, a &#x003b2;(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.</article-title>
<source>Eur Urol</source>
<year>2013</year>; <volume>63</volume>: <fpage>283</fpage>-<lpage>95</lpage>.<annotation><p><italic toggle="yes">(Among 1978 patients with overactive bladder syndrome treated with once daily mirabegron [50 or 100 mg], tolterodine [4 mg] or placebo for 12 weeks, adverse event rates were similar among groups, and "changes in...serum chemistry parameters...were small and consistent across treatment groups").</italic></p></annotation><pub-id pub-id-type="pmid">23182126</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.chapple.2013.1447">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chapple</surname>
<given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Dvorak</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Radziszewski</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Van Kerrebroeck</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wyndaele</surname>
<given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Bosman</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Boerrigter</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>; <collab>Dragon Investigator Group</collab>. <article-title>A phase II dose-ranging study of mirabegron in patients with overactive bladder.</article-title>
<source>Int Urogynecol J</source>
<year>2013</year>; <volume>24</volume>: <fpage>1447</fpage>-<lpage>58</lpage>.<annotation><p><italic toggle="yes">(Among 928 adults with overactive bladder treated with mirabegron [25, 50, 100 or 200 mg daily], there was a dose related reduction in frequency of micturition, and side effects included increase in pulse rate at the high doses, but "there were no clinically relevant changes in laboratory parameters").</italic></p></annotation><pub-id pub-id-type="pmid">23471546</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.otsuki.2013.53">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Otsuki</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kosaka</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nakamura</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mishima</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kuwahara</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tsukamoto</surname>
<given-names>T.</given-names></string-name>
<article-title>&#x003b2;3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.</article-title>
<source>Int Urol Nephrol</source>
<year>2013</year>; <volume>45</volume>: <fpage>53</fpage>-<lpage>60</lpage>.<annotation><p><italic toggle="yes">(Among 97 patients with overactive bladder treated with mirabegron [50 mg daily] for 8 weeks, 74% had improvement in symptoms and there was no liver related adverse events).</italic></p></annotation><pub-id pub-id-type="pmid">23212147</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF8">
            <mixed-citation publication-type="journal"><article-title>Mirabegron (Myrbetriq) for overactive bladder.</article-title>
<source>Med Lett Drugs Ther</source>
<year>2013</year>; <volume>55</volume> (<issue>1410</issue>): <fpage>13</fpage>-<lpage>5</lpage>.<annotation><p><italic toggle="yes">(Concise review of mechanism of action, clinical efficacy, safety and costs of mirabegron and other treatments for overactive bladder syndrome; mentions side effects of nausea, diarrhea, constipation, dizziness, tachycardia and headache, but not ALT elevations or hepatotoxicity).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.bj_rnsson.2013.1419">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bj&#x000f6;rnsson</surname>
<given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Bergmann</surname>
<given-names>OM</given-names></string-name>, <string-name name-style="western"><surname>Bj&#x000f6;rnsson</surname>
<given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Kvaran</surname>
<given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Olafsson</surname>
<given-names>S</given-names></string-name>. <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
<source>Gastroenterology</source>
<year>2013</year>; <volume>144</volume>: <fpage>1419</fpage>-<lpage>25</lpage>.<annotation><p><italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to mirabegron).</italic></p></annotation><pub-id pub-id-type="pmid">23419359</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.nitti.2014.972">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nitti</surname>
<given-names>VW</given-names></string-name>, <string-name name-style="western"><surname>Chapple</surname>
<given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Walters</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Blauwet</surname>
<given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Herschorn</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Milsom</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Auerbach</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Safety and tolerability of the &#x003b2;3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.</article-title>
<source>Int J Clin Pract</source>
<year>2014</year>; <volume>68</volume>: <fpage>972</fpage>-<lpage>85</lpage>.<annotation><p><italic toggle="yes">(Pooled analysis of safety of mirabegron [25, 50 and 100 mg daily] from three 12-week and one 1-year studies reported side effects of hypertension, headache, back pain, drug mouth and constipation low and similar to rates in placebo recipients; elevations in ALT above 3 times ULN occurred in 1.5% on mirabegron, 1.4% on placebo and 2.0% on tolterodine, and no patient had concurrent elevation in bilirubin or clinically apparent liver injury).</italic></p></annotation><pub-id pub-id-type="pmid">24703195</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.hern_ndez.2014.231">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hern&#x000e1;ndez</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bessone</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>S&#x000e1;nchez</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>di Pace</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brahm</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zapata</surname>
<given-names>R, A</given-names></string-name>
<string-name name-style="western"><surname>Chirino</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>
<article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
<source>Ann Hepatol</source>
<year>2014</year>; <volume>13</volume>: <fpage>231</fpage>-<lpage>9</lpage>.<annotation><p><italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, but none were attributed to mirabegron).</italic></p></annotation><pub-id pub-id-type="pmid">24552865</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.chalasani.2015.1340">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chalasani</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bonkovsky</surname>
<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stolz</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Talwalkar</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname>
<given-names>KR</given-names></string-name>, <etal>et al.</etal>; <collab>United States Drug Induced Liver Injury Network</collab>. <article-title>Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.</article-title>
<source>Gastroenterology</source>
<year>2015</year>; <volume>148</volume>: <fpage>1340</fpage>-<lpage>1352.e7</lpage>.<annotation><p><italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to mirabegron or other agents for overactive bladder syndrome).</italic></p></annotation><pub-id pub-id-type="pmid">25754159</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.batista.2015.167">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Batista</surname>
<given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>K&#x000f6;lbl</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Herschorn</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rechberger</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cambronero</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Halaska</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Coppell</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>; <collab>BEYOND study group</collab>. <article-title>The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.</article-title>
<source>Ther Adv Urol</source>
<year>2015</year>; <volume>7</volume>: <fpage>167</fpage>-<lpage>79</lpage>.<annotation><p><italic toggle="yes">(Among 1887 patients with overactive bladder treated with mirabegron or solifenacin for 12 weeks, decreases in micturition rates were similar with the two drugs [3.0 and 3.1 per day] as were rates of adverse events; no mention of ALT levels or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">26445596</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.thiagamoorthy.2015.445">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Thiagamoorthy</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cardozo</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Srikrishna</surname>
<given-names>S</given-names></string-name>. <article-title>Drug therapy for an overactive bladder.</article-title>
<source>Womens Health (Lond)</source>
<year>2015</year>; <volume>11</volume>: <fpage>445</fpage>-<lpage>8</lpage>.<annotation><p><italic toggle="yes">(Overactive bladder is defined as urinary urgency, usually with frequency and nocturia with or without incontinence in the absence of infection or other known cause; medical therapy being use of anticholinergics or beta-3 agonists such as mirabegron which has fewer side effects than typical anticholinergics).</italic></p></annotation><pub-id pub-id-type="pmid">26238677</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.warren.2016.204">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Warren</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Burden</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Abrams</surname>
<given-names>P</given-names></string-name>. <article-title>Mirabegron in overactive bladder patients: efficacy review and update on drug safety.</article-title>
<source>Ther Adv Drug Saf</source>
<year>2016</year>; <volume>7</volume>: <fpage>204</fpage>-<lpage>216</lpage>.<annotation><p><italic toggle="yes">(Review of the 3 phase III trials of mirabegron for overactive bladder syndrome; no discussion of liver related adverse events).</italic></p></annotation><pub-id pub-id-type="pmid">27695622</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.kallner.2016.167">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kallner</surname>
<given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Christensson</surname>
<given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Elm&#x000e9;r</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Flam</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname>
<given-names>D</given-names></string-name>. <article-title>Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study.</article-title>
<source>Eur J Obstet Gynecol Reprod Biol</source>
<year>2016</year>; <volume>203</volume>: <fpage>167</fpage>-<lpage>72</lpage>.<annotation><p><italic toggle="yes">(Among 221 women with overactive bladder syndrome treated in clinical practice at a single medical center, 16 patients stopped therapy because of side effects including palpitations, chest pain, dry mouth, diarrhea, headache, fatigue, blurred vision and edema; no mention of liver related adverse events).</italic></p></annotation><pub-id pub-id-type="pmid">27318184</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.blais.2016.9">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Blais</surname>
<given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Nadeau</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Genois</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bolduc</surname>
<given-names>S</given-names></string-name>. <article-title>Prospective pilot study of mirabegron in pediatric patients with overactive bladder.</article-title>
<source>Eur Urol</source>
<year>2016</year>; <volume>70</volume>: <fpage>9</fpage>-<lpage>13</lpage>.<annotation><p><italic toggle="yes">(Among 58 children with overactive bladder treated with mirabegron for a median of 11 months, bladder capacity increased and incontinence decreased, while most children tolerated therapy with no change in pulse or blood pressure and infrequent symptoms of nausea, personality change and nasal stuffiness; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">26876327</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.sager.2020.655.e1">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sager</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sanmartino</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Burek</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gomez</surname>
<given-names>YR</given-names></string-name>, <string-name name-style="western"><surname>Vazquez Pati&#x000f1;o</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weller</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ruiz</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction.</article-title>
<source>J Pediatr Urol.</source>
<year>2020</year>;<volume>16</volume>:<fpage>655.e1</fpage>-<lpage>655.e6</lpage>.<annotation><p><italic toggle="yes">(Among 37 children with neurogenic bladder dysfunction treated with mirabegron [25 mg daily], bladder capacity increased, while therapy was well tolerated, and ALT and AST values did not change).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.bakaostrowska.2021.1490">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Baka-Ostrowska</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bolong</surname>
<given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Persu</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>T&#x000f8;ndel</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Steup</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lademacher</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname>
<given-names>N</given-names></string-name>. <article-title>Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study.</article-title>
<source>Neurourol Urodyn.</source>
<year>2021</year>;<volume>40</volume>:<fpage>1490</fpage>-<lpage>1499</lpage>.<annotation><p><italic toggle="yes">(Among 86 children ages 3 to 18 years treated with mirabegron [25 to 50 mg daily] for up to 24 weeks, bladder capacity was increased, while adverse events arose in 59% of patients but few were considered related with therapy; no mention of ALT elevations but one patient had transient, mild creatine kinase and AST elevations).</italic></p></annotation><pub-id pub-id-type="pmid">34058027</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.soliman.2021.1011">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Soliman</surname>
<given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>El-Abd</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>El-Gamal</surname>
<given-names>OM</given-names></string-name>, <string-name name-style="western"><surname>Raheem</surname>
<given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Abou-Ramadan</surname>
<given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>El-Abd</surname>
<given-names>AS</given-names></string-name>. <article-title>Mirabegron versus solifenacin in children with overactive bladder: prospective randomized single-blind controlled trial.</article-title>
<source>Urol Int.</source>
<year>2021</year>;<volume>105</volume>:<fpage>1011</fpage>-<lpage>1017</lpage>.<annotation><p><italic toggle="yes">(Among 190 children ages 5 to 14 years with overactive bladder syndrome treated with mirabegron [50 mg], solifenacin [5 mg], or placebo once daily for 3 months, clinical responses were higher with medical therapy [88% and 90% vs 56%], while adverse events included dry mouth [3% and 10% vs 0%], constipation [3% and 11% vs 1%]; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">34010843</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF.kinjo.2023.67">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kinjo</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Masuda</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nakamura</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Miyakawa</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tambo</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fukuhara</surname>
<given-names>H</given-names></string-name>. <article-title>Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: A randomized controlled study.</article-title>
<source>Urology.</source>
<year>2023</year>;<volume>175</volume>:<fpage>67</fpage>-<lpage>73</lpage>.<annotation><p><italic toggle="yes">(Among 199 adult women with overactive bladder syndrome treated with 50 mg of either mirabegron or vibegron daily for 12 weeks, response rates were similar in both groups as were overall rates of adverse events [17.5% vs 15.7%], discontinuations [6.2% vs 6.8%], constipation [10.3% vs 11.8%], dry mouth [both 1%], and rash [2% vs 1%]; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">36822245</pub-id></mixed-citation>
          </ref>
          <ref id="Mirabegron.REF22">
            <mixed-citation publication-type="journal"><article-title>Drugs for overactive bladder.</article-title>
<source>Med Lett Drugs Ther.</source>
<year>2023</year>;<volume>65</volume>:<fpage>41</fpage>-<lpage>45</lpage>.<annotation><p><italic toggle="yes">(Concise review of drugs approved for therapy of overactive bladder in the US including anticholinergic agents [darifenacin, fesoterodine, oxbutynin, solifenacin, tolterodine and trospium] and beta-3 adrenergic receptor agonists [mirabegron and vibegron] including clinical efficacy, safety, and costs; no mention of ALT elevations or hepatotoxicity of any of the agent discussed).</italic></p></annotation><pub-id pub-id-type="pmid">36897601</pub-id></mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Mirabegron.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Mirabegron+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Mirabegron: from PubMed.gov</ext-link>
</p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Mirabegron">Trials on Mirabegron: from ClinicalTrials.gov</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
